Alterity Therapeutics Q4 FY25 Quarterly Cash Flow Report and Clinical Trial Updates

SEC Filing 6-K (0001213900-25-068955)

Alterity Therapeutics Limited released its Q4 FY25 Quarterly Cash Flow Report, highlighting significant milestones in its clinical trials for ATH434, a treatment for Multiple System Atrophy (MSA). The U.S. FDA granted Fast Track Designation for ATH434, recognizing its potential to address the unmet needs of MSA patients. Positive topline data from the open-label Phase 2 clinical trial of ATH434 in MSA showed clinical benefits and favorable safety profiles. The company also reported a cash balance of A$40.66M as of 30 June 2025, with operating cash outflows of A$2.35M for the quarter. Additional analyses from the ATH434-201 trial demonstrated robust efficacy, and the company presented these findings at prominent medical meetings. Alterity continues to advance its MSA program, preparing for interactions with the U.S. FDA.